Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic review
- PMID: 31209080
- PMCID: PMC6588972
- DOI: 10.1136/bmjopen-2018-022271
Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic review
Abstract
Introduction: Dual antiplatelet therapy (DAPT) is routinely given to patients after percutaneous coronary intervention (PCI) with stenting; however, there is ongoing debate about the optimal duration, especially in specific patient groups. In the proposed systematic review, we intend to assess the optimal duration of DAPT following PCI with stenting, with a focus on clinically relevant patient subgroups.
Methods and analysis: We will perform a comprehensive search of the published literature for randomised controlled trials (RCTs) assessing the benefits and harms of extended DAPT (>12 months) compared with short-term DAPT (6-12 months) following PCI with stenting (bare metal or drug eluting). ClinicalTrials.gov and ICTRP will also be searched to identify ongoing and completed clinical trials. Two independent reviewers will select studies for inclusion, and the risk of bias will be assessed by use of Cochrane's Risk of Bias tool. The primary outcome of interest is death (all-cause, cardiovascular, non-cardiovascular). Secondary outcomes are bleeding (major, minor, gastrointestinal), urgent target vessel revascularisation, major adverse cardiovascular events, myocardial infarction, stroke and stent thrombosis. Subgroup data will be sought for patients with prior myocardial infarction, acute coronary syndrome at presentation and diabetes, and based on smoking status and age group. Data will be analysed by random-effects meta-analysis, and separate analyses will be performed for patient subgroups. Bayesian network meta-analysis will be performed to investigate the effect of individual P2Y12 inhibitors at different DAPT durations longer than 6 months.
Ethics and dissemination: This review will provide a comprehensive overview of the available evidence of the benefits and harms associated with extending DAPT beyond 12 months following PCI with stenting and the effects on clinically important subgroups. The results of this review will inform clinical and policy decisions regarding the optimal treatment duration of DAPT following PCI with stenting.
Systematic review registration: PROSPERO no. CRD42018082587.
Keywords: dapt; dual antiplatelet therapy; percutaneous intervention.
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Extended dual antiplatelet therapy following percutaneous coronary intervention in clinically important patient subgroups: a systematic review and meta-analysis.CMAJ Open. 2023 Feb 7;11(1):E118-E130. doi: 10.9778/cmajo.20210119. Print 2023 Jan-Feb. CMAJ Open. 2023. PMID: 36750248 Free PMC article.
-
Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review.BMJ Open. 2017 Apr 4;7(4):e015421. doi: 10.1136/bmjopen-2016-015421. BMJ Open. 2017. PMID: 28377396 Free PMC article.
-
Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.Eur Heart J. 2021 Jan 21;42(4):308-319. doi: 10.1093/eurheartj/ehaa739. Eur Heart J. 2021. PMID: 33284979
-
Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.Am Heart J. 2021 Jun;236:49-58. doi: 10.1016/j.ahj.2021.02.014. Epub 2021 Feb 20. Am Heart J. 2021. PMID: 33621541
-
Meta-analysis of Dual Antiplatelet Therapy Versus Monotherapy With P2Y12 Inhibitors in Patients After Percutaneous Coronary Intervention.Am J Cardiol. 2020 Jul 15;127:25-29. doi: 10.1016/j.amjcard.2020.04.027. Epub 2020 Apr 22. Am J Cardiol. 2020. PMID: 32389351 Review.
Cited by
-
Extended dual antiplatelet therapy following percutaneous coronary intervention in clinically important patient subgroups: a systematic review and meta-analysis.CMAJ Open. 2023 Feb 7;11(1):E118-E130. doi: 10.9778/cmajo.20210119. Print 2023 Jan-Feb. CMAJ Open. 2023. PMID: 36750248 Free PMC article.
-
The predictive value of the ARC-HBR criteria for in-hospital bleeding risk following percutaneous coronary intervention in patients with acute coronary syndrome.Int J Cardiol Heart Vasc. 2024 Oct 19;55:101527. doi: 10.1016/j.ijcha.2024.101527. eCollection 2024 Dec. Int J Cardiol Heart Vasc. 2024. PMID: 39498347 Free PMC article.
References
-
- Valgimigli M, Bueno H, Byrne RA, et al. . 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213–60. 10.1093/eurheartj/ehx419 - DOI - PubMed
-
- Levine GN, Bates ER, Mauri L, et al. . Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease a report of the American College of Cardiology / American heart association task force on clinical practice guidelines. Circulation 2016;133. - PubMed
-
- Wells GA, Elliott J, Kelly S, et al. . Dual Antiplatelet Therapy following Percutaneous Coronary Intervention: a Review of the Clinical Impact of Treatment Duration. University of Ottawa: Ottawa, ON, 2017. https://cadth.ca/sites/default/files/pdf/HT0001_DAPT_Post_PCI_.pdf [Accessed 11 Feb 2019]. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous